Semax 10mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of Semax supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety. Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques. Batch: GF092025040 Key analytical results include:

• Assay Content: 10.90 mg
• Identification – Retention Time: 0.999
• Identification – Spectrum: 997
• Purity: greater than 99.8 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium. These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

Semax is a synthetic peptide research compound frequently studied in controlled laboratory environments examining neuropeptide signalling pathways and regulatory peptide interactions. The compound is a modified analogue derived from fragments of adrenocorticotropic hormone (ACTH) and has been investigated in experimental models exploring neurochemical signalling and peptide-mediated regulatory pathways. This preparation contains 10 mg of high purity lyophilized peptide supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation. Because of its defined peptide structure and stable analytical profile, Semax has become a widely referenced compound in experimental neuropeptide research models.

Compound Overview

Semax is a synthetic heptapeptide analogue derived from fragments of the endogenous hormone adrenocorticotropic hormone (ACTH). ACTH-derived peptides are known to interact with regulatory signalling pathways involved in neurochemical communication and molecular signalling networks. Research involving Semax often explores its interaction with neurotransmitter systems, neuropeptide signalling mechanisms and intracellular regulatory pathways. Due to its defined molecular structure and biochemical stability, Semax is widely used in controlled laboratory environments investigating neuropeptide-mediated cellular communication.

Historical Background and Scientific Context

Scientific interest in neuropeptide signalling expanded significantly during the late twentieth century as advances in peptide chemistry enabled the development of synthetic peptide analogues. Researchers began examining derivatives of endogenous hormonal peptides capable of interacting with complex cellular signalling systems. Semax emerged from this research as a synthetic peptide analogue derived from ACTH fragments and used in experimental models investigating neurochemical signalling mechanisms. Subsequent studies have explored how peptide analogues interact with receptor systems and intracellular signalling networks.

Mechanistic Focus in Research

Within experimental laboratory settings, Semax is commonly studied in relation to neuropeptide signalling and peptide-mediated regulatory pathways. Research investigations commonly explore the compound in experimental models examining:

• Neuropeptide signalling pathways
• Neurotransmitter regulatory systems
• Peptide receptor interaction mechanisms
• Molecular signalling network modelling
• Comparative peptide signalling research
• Intracellular regulatory pathway analysis
• Neurochemical communication mechanisms

These experimental models allow scientists to investigate molecular signalling mechanisms that influence neurochemical communication and cellular regulatory processes.

Research Applications

In controlled research environments, Semax may be utilised in experimental models designed to explore neuropeptide signalling and regulatory peptide systems. Examples of research applications include:

• Neuropeptide signalling studies
• Neurochemical pathway investigation
• Peptide receptor interaction analysis
• Molecular signalling research
• Comparative peptide compound evaluation
• Intracellular regulatory network modelling
• Controlled in vitro peptide studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation. Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

• Verified and analysed with Liquilabs s.r.o. Czechia
• Above 99.8 percent purity with validated assay content
• No detectable heavy metals or microbial contamination
• Endotoxin below 0.001 EU per mg
• Batch GF092025040 – Published October 2025
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.